LYN and cutaneous mastocytosis: Data from a phase 2 study in patients with systemic or cutaneous mastocytosis (N = 25) treated with the KIT/LYN kinase inhibitor masitinib, however, demonstrated an ORR of 56.0 % and modest improvements in symptoms and quality-of-life measurements after 12 weeks of treatment (Paul et al. 2010).